GLPwatch

Mirikizumab Administered at the Same Time as Tirzepatide in Adult Participants With Moderately to Severely Active Ulcerative Colitis and Obesity or Overweight: Phase 3b Study

NCT06937086 · Recruiting

Last updated 2026-05-28

This clinical trial is testing whether combining two medications, mirikizumab and tirzepatide, can help adults with moderately to severely active ulcerative colitis and obesity or overweight achieve both disease remission and significant weight loss.

Status Recruiting Currently enrolling participants.
Phase Phase 3 Confirms effectiveness in a large group before approval.
Type Interventional (clinical trial)
Design Randomized, double-blind treatment study
Participants 350 people Planned (estimated).
Who can join Ages 18–70 · all sexes
Timeline Started 2025-06 · est. completion 2028-04
Where 190 sites · Austria, Belgium, Brazil, Bulgaria, Canada, Czechia, Denmark, France, Germany, Greece, Hungary, Israel, Italy, Mexico, Netherlands, Poland, Puerto Rico, Romania, Slovakia, Spain, Turkey (Türkiye), United Kingdom, United States

What this study is testing ClinicalTrials.gov NCT06937086 ↗

Description as written by the study sponsor.

The main purpose of this study is to show whether in these individuals, treatment with both mirikizumab and tirzepatide, compared with treatment with mirikizumab and placebo, leads to decrease or disappearance of UC symptoms, and loss of at least one-tenth of the overall body weight. Participation in this study will last up to 61 weeks, including 52 weeks of treatment.

Treatments tested

Main thing measuredPercentage of Participants Who Simultaneously Achieve Clinical Remission and at Least 10% Weight Reduction
SponsorEli Lilly and Company
Conditions studiedUlcerative Colitis, Obesity or Overweight
GLP-1 drugs tirzepatide

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT06937086 ↗